Takeda and Neurocrine Collaborate for Seven Neuro Programs Worth Up to $2B

Shots:

• Takeda to receive $120M as upfront in cash, ~ $495M as development milestones, and ~$1.4B as commercial milestones along with royalties on net sales of the therapies. Takeda retains the ability to opt-in or out of a 50:50 profit share on all clinical programs at certain development events
• For any asset in which Takeda shares equal profit, Takeda will not receive development or commercial milestones. Neurocrine get an exclusive license for seven pipeline programs, including three clinical-stage assets for schizophrenia, treatment-resistant depression, and anhedonia
• The collaboration involves three clinical program includes TAK-831, TAK-653, TAK-041 and the rights to four preclinical programs

Click here to read full press release/ article | Ref: Takeda | Image: Future Medicine India